Linichlorin A
Linichlorin A is a p27Kip1 ubiquitination inhibitor that blocks p27Kip1 degradation by inhibiting the Skp2-Cks1–p27Kip1 interaction. Linichlorin A shows selective antiproliferative activity against tumor cells. Linichlorin A induces apoptosis in leukemia cells via cytochrome c release, caspase activation and PARP cleavage. Linichlorin A can be used in the study of leukemia, melanoma, cervical cancer and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 62462-98-0
- Formula: C19H23ClO6
- Molecular Weight:382.84
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Caspase-3 |
Caspase-7 |
Caspase-8 |
Caspase-9 |
CDK |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NIH3T3 | IC50 |
12.7 μM
Compound: Linichlorin A
|
Antiproliferative activity against mouse NIH/3T3 cells
Antiproliferative activity against mouse NIH/3T3 cells
|
30108998 |
| HeLa | IC50 |
3.2 μM
Compound: Linichlorin A
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
30108998 |
| HeLa | IC50 |
3.2 μM
Compound: Linichlorin A
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 30108998] |
| NIH3T3 | IC50 |
12.7 μM
Compound: Linichlorin A
|
Antiproliferative activity against mouse NIH/3T3 cells
Antiproliferative activity against mouse NIH/3T3 cells
|
[PMID: 30108998] |
| HL-60 | IC50 |
1.2 μM
|
Shows growth inhibitory activity against HL-60 cells.
Shows growth inhibitory activity against HL-60 cells.
|
33371413 |
| U-937 | IC50 |
1.9 μM
|
Shows growth inhibitory activity against U-937 cells.
Shows growth inhibitory activity against U-937 cells.
|
33371413 |
| SK-MEL-1 | IC50 |
3.6 μM
|
Shows growth inhibitory activity against SK-MEL-1 cells.
Shows growth inhibitory activity against SK-MEL-1 cells.
|
33371413 |
In Vitro
Linichlorin A (72 h) shows growth inhibitory activity against HL-60, U-937, U-937/Bcl-2 and SK-MEL-1 cells with IC50 values of 1.2, 1.9, 2.9 and 3.6 μM, respectively[1].
Linichlorin A (48 h) shows selective antiproliferative activity against HeLa, tsFT210 and NIH3T3 cells with IC50 values of 3.2, 1.6 and 12.7 μM, respectively[2].
Linichlorin A (10 μM; 24 h) induces significant morphological changes and a marked reduction in cell number in HL-60, U-937, U-937/Bcl-2 and SK-MEL-1 cells as observed by inverted phase-contrast microscopy[1].
Linichlorin A (10 μM; 24 h) induces typical apoptosis in U-937 cells as determined by flow cytometry: the sub-G1 apoptotic cell fraction increases significantly, and Annexin V-FITC staining reveals phosphatidylserine externalization[1].
Linichlorin A (10 μM; 24 h) stimulates caspase activity and processing in U-937 cells (caspase-9, -8 and -3/7 activities increase approximately 4-, 3- and 7-fold, respectively; Western blotting shows processing of pro-caspase-3, -8 and -9), and induces downstream PARP cleavage (116 kDa → 85 kDa)[1].
Linichlorin A (3 μM and 10 μM; 24 h) induces concentration-dependent release of cytochrome c from mitochondria to cytosol in U-937 cells, with 3 μM being sufficient[1].
Linichlorin A (10 μM; 24 h) still induces apoptosis (sub-G₁ fraction increases approximately 11-fold) in Bcl-2-overexpressing U-937/Bcl-2 cells, and Bcl-2 overexpression does not confer significant protection[1].
Linichlorin A (60 μg/mL) inhibits the binding of Skp2-Cks1 to p27Kip1 phosphopeptides in a fluorescence-based high-throughput screening assay[2].
Linichlorin A (3.2 μM) inhibits the in vitro ubiquitination of p27Kip1 (approximately 70-80% reduction)[2].
Linichlorin A (3.2 μM; 18 h) stabilizes p27Kip1 protein levels by inhibiting its degradation in HeLa cells, without affecting p27Kip1 mRNA expression[2].
Linichlorin A (1-10 μM; 18 h) upregulates p27Kip1 protein expression in tsFT210 cells in a dose-dependent manner[2].
Linichlorin A (1.6 μM; 8-12 h) delays G1-S phase progression and significantly increases p27Kip1 protein levels in tsFT210 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HL-60, U-937, U-937/Bcl-2 and SK-MEL-1 cells
-
Concentration:1, 10, 30 and 100 μM
-
Incubation Time:72 h
-
Result:Showed growth inhibitory activity with IC50 values of 1.2, 1.9, 2.9 and 3.6 μM, respectively.
-
Cell Line:U-937 and HL-60 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Showed fragmented and condensed chromatin characteristic of apoptotic cell death after Hoechst 33258 staining.
-
Cell Line:U-937 and HL-60 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly increased the percentage of apoptotic cells in the sub-G₁ fraction (approximately 12-fold in U-937 and 13-fold in HL-60 compared with control) as determined by flow cytometry after propidium iodide staining.
-
Cell Line:U-937 cells (and U-937/Bcl-2 for the last result)
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Induced phosphatidylserine externalization (Annexin V‑FITC positive); stimulated caspase‑9, ‑8 and ‑3/7 activities (approximately 4‑, 3‑ and 7‑fold increases, respectively, by colorimetric substrates); in Bcl‑2‑overexpressing U‑937/Bcl‑2 cells, still induced apoptosis (approximately 11‑fold increase in sub‑G₁ fraction) without significant protection.
-
Cell Line:U-937 cells
-
Concentration:10 μM (for PARP and caspase processing) / 3 μM and 10 μM (for cytochrome c)
-
Incubation Time:24 h
-
Result:Induced PARP cleavage (116 kDa full-length to 85 kDa fragment); induced concentration‑dependent release of cytochrome c from mitochondria to cytosol (3 μM was sufficient); showed processing of pro‑caspase‑3, ‑8 and ‑9.
-
Cell Line:tsFT210 cells
-
Concentration:1.6 μM
-
Incubation Time:8 h and 12 h
-
Result:Delayed G₁‑S phase progression in tsFT210 cells. After G₂ synchronization at 39°C for 18 h, cells released at 32°C showed a decreased percentage of S phase cells at 8 h and 12 h compared with control, as determined by flow cytometry after propidium iodide staining.
-
Cell Line:HeLa cells
-
Concentration:3.2 μM
-
Incubation Time:18 h
-
Result:Showed no significant effect on p27Kip1 mRNA expression level compared with DMSO control, as determined by semi‑quantitative RT‑PCR.
-
Cell Line:HeLa cells
-
Concentration:3.2 μM
-
Incubation Time:18 h
-
Result:Inhibited p27Kip1 degradation and stabilized its protein level in the CHX chase assay.
-
Cell Line:tsFT210 cells
-
Concentration:1, 3 and 10 μM (for dose‑dependent study); 1.6 μM (for cell cycle study)
-
Incubation Time:18 h (for dose‑dependent study); 8‑12 h (for cell cycle study)
-
Result:Upregulated p27Kip1 protein expression in a dose‑dependent manner at 1‑10 μM for 18 h; significantly increased p27Kip1 protein levels during G₁‑S progression at 1.6 μM for 8‑12 h.
-
Cell Line:NIH3T3 cells
-
Concentration:10 μM
-
Incubation Time:18 h
-
Result:Showed lower p27Kip1 upregulation compared with tsFT210 cells.
Chemical Information
-
CAS No. 62462-98-0
-
Molecular Weight 382.84
-
Formula C19H23ClO6
-
SMILES
C(Cl)[C@]1(O)[C@@]2([C@@]3([C@@]([C@@H](OC(C(C)=C)=O)CC(=C)[C@@]2(C[C@@H]1O)[H])(C(=C)C(=O)O3)[H])[H])[H]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Estévez-Sarmiento F, et al. Chlorinated Guaiane-Type Sesquiterpene Lactones as Cytotoxic Agents against Human Tumor Cells. Int J Mol Sci. 2020 Dec 21;21(24):9767. [Content Brief]
[2]. Ooi LC, et al. Identification of small molecule inhibitors of p27(Kip1) ubiquitination by high-throughput screening. Cancer Sci. 2013 Nov;104(11):1461-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Linichlorin A
- 62462-98-0
- Caspase
- Apoptosis
- PARP
- p27Kip1
- p27Kip1 ubiquitination inhibitor
- apoptosis
- caspase activation
- HL-60
- U-937
- U-937/Bcl-2
- SK-MEL-1
- growth inhibition
- caspase activation
- PARP cleavage
- cytochrome c release
- leukemia
- melanoma
- HeLa
- tsFT210
- NIH3T3
- Skp2
- Cks1
- ubiquitination
- cell cycle
- G? S phase
- CHX chase assay
- protein stability
- mRNA expression
- high throughput screening
- anticancer
- Inhibitor
- inhibitor
- inhibit